AR044649A1 - COMPUESTOS UTILES EN LA TERAPIA DE ENFERMEDADES QUE REQUIEREN LA INHIBICION DE UNA 17a - HIDROXIESTEROIDE - DEHIDROGENASA (17a- HSD) - Google Patents
COMPUESTOS UTILES EN LA TERAPIA DE ENFERMEDADES QUE REQUIEREN LA INHIBICION DE UNA 17a - HIDROXIESTEROIDE - DEHIDROGENASA (17a- HSD)Info
- Publication number
- AR044649A1 AR044649A1 ARP040101982A ARP040101982A AR044649A1 AR 044649 A1 AR044649 A1 AR 044649A1 AR P040101982 A ARP040101982 A AR P040101982A AR P040101982 A ARP040101982 A AR P040101982A AR 044649 A1 AR044649 A1 AR 044649A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- optionally substituted
- cycle
- alkylene group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 101710088194 Dehydrogenase Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004122 cyclic group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- -1 C1-8-alkyl radicals Chemical class 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 150000005840 aryl radicals Chemical class 0.000 abstract 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 2
- 125000005110 aryl thio group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 150000002923 oximes Chemical class 0.000 abstract 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 239000003270 steroid hormone Substances 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 229930192474 thiophene Natural products 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 125000005157 alkyl carboxy group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000950 dibromo group Chemical group Br* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Abstract
Compuestos útiles en la terapia, especialmente para el tratamiento y/o prevención de una afección dependiente de una hormona esteroide, preferiblemente una enfermedad o afección dependiente de una hormona esteroide que requiere la inhibición de una 17b-hidroxiesteroide-dehidrogenasa (17b-HSD) tal como enzima 17b-HSD tipo 1, tipo 2 o tipo 3. Reivindicación 3: Compuestos de la fórmula (1), en la cual: R1 y R2 representan radicales C1-8-alquilo, iguales o distintos entre sí o uno de ellos es C1- 8-alquilo y el otro es H; o R1 y R2 forman conjuntamente con los átomos de carbonos a los cuales están ligados un sistema cíclico de 5-, 6-, 7- u 8 miembros, saturado o que contiene uno o más dobles ligaduras entre los átomos del cíclico, conteniendo dicho ciclo opcionalmente hasta dos átomos de nitrógeno en adición al átomo de nitrógeno al que está fijado R1, estando dicho ciclo opcionalmente sustituido con hasta dos sustituyentes independientemente elegidos del grupo que comprende alquilo, alquilo sustituido, arilo, o arilalquilo, cuyo radical arilo está opcionalmente sustituido, alcoxi, ariloxi, aciloxi, ariltio, alquiltio, arilsulfonilo, alquilsulfonilo, hidroxilo, oxo, halógeno, amino, oxima, acilo, tiocarboxilo y amido; la cadena de hidrocarburo -C(R5)-C(R6)C(CH)n- del sistema cíclico adyacente al ciclo tiofeno es saturada o contiene una o más dobles ligaduras entre los átomos de carbono; n es un número de 1 a 4; y R5 y R6 están individualmente elegidos del grupo que comprende hidrógeno, alquilo, alquilo sustituido, arilo o arilquilo, cuyo radical arilo está opcionalmente sustituido, alcoxi, ariloxi, aciloxi, ariltio, alquiltio, arilsulfonilo, alquilsulfonilo, hidroxilo, oxo, halógeno, amino, oxima, acilo, carboxilo, tiocarboxilo, y amido; con la condición que en el caso en que n representa los números 1, 2 ó 3, y R1 y R2 están independientemente seleccionados del grupo que comprende hidrógeno, o C1-4-alquilo o que en conjunto forman un grupo alquileno no sustituido de tres a cinco grupos metileno o un grupo imino-alquileno de dos a cuatro grupos metileno en el grupo alquileno, opcionalmente sustituido en el átomo de N, entonces al menos R5 o R6 debe ser distinto de hidrógeno, C1-4- alquilo o alquilcarboxilo, o la cadena de hidrocarburo C(R5)C(R6)-(CH)n del sistema cíclico adyacente al ciclo tiofeno debe ser insaturado o aromática; en el caso en que n representa 2 y R1-R2 forman un grupo alquileno no sustituido de 3 a 5 grupos metileno, entonces R6 debe ser distinto de bromo, dibromo o feniltio, si R5 representa un grupo hidroxilo u oxo; o en el caso en que n representa 2 y R1-R2 forman un grupo pentametileno no sustituido, R5 deber ser distinto de feniltio si R6 representa carbonilo, para uso en terapia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47701703P | 2003-06-10 | 2003-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044649A1 true AR044649A1 (es) | 2005-09-21 |
Family
ID=33551663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101982A AR044649A1 (es) | 2003-06-10 | 2004-06-08 | COMPUESTOS UTILES EN LA TERAPIA DE ENFERMEDADES QUE REQUIEREN LA INHIBICION DE UNA 17a - HIDROXIESTEROIDE - DEHIDROGENASA (17a- HSD) |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7754709B2 (es) |
| EP (1) | EP1635840B1 (es) |
| JP (1) | JP4612628B2 (es) |
| CN (1) | CN100502876C (es) |
| AR (1) | AR044649A1 (es) |
| AT (1) | ATE401893T1 (es) |
| AU (1) | AU2004246791B2 (es) |
| BR (1) | BRPI0411319A (es) |
| CA (1) | CA2527591A1 (es) |
| DE (1) | DE602004015287D1 (es) |
| DK (1) | DK1635840T3 (es) |
| ES (1) | ES2311156T3 (es) |
| PL (1) | PL1635840T3 (es) |
| PT (1) | PT1635840E (es) |
| SA (1) | SA04250158B1 (es) |
| TW (1) | TW200504078A (es) |
| WO (1) | WO2004110459A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| JP2008517061A (ja) * | 2004-10-20 | 2008-05-22 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | 抗腫瘍剤としての化合物及びそれらの使用 |
| BRPI0419229A (pt) * | 2004-12-13 | 2007-12-18 | Solvay Pharm Gmbh | derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| EP2013176A2 (en) * | 2006-02-27 | 2009-01-14 | Sterix Limited | Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer |
| EP1990335A4 (en) | 2006-03-02 | 2009-11-11 | Astellas Pharma Inc | 17-BETA-HSD-type-5 INHIBITOR |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| DE102007040243A1 (de) | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| GB0722779D0 (en) | 2007-11-20 | 2008-01-02 | Sterix Ltd | Compound |
| NZ589691A (en) * | 2008-05-05 | 2012-11-30 | Merck Patent Gmbh | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| WO2012025638A1 (en) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| WO2012119605A1 (en) * | 2011-03-10 | 2012-09-13 | Akar Yahya Ahmed Abdellhafeez Salem | New disperse dye with potent anticancer activity |
| WO2014207311A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| KR20160042873A (ko) | 2013-06-25 | 2016-04-20 | 포렌도 파마 리미티드 | 17.베타.-하이드록시스테로이드 탈수소효소의 억제제로서 치료적 활성 17-질소 치환된 에스트라트리엔티아졸 유도체 |
| EP3089969A2 (en) | 2014-01-03 | 2016-11-09 | Elexopharm GmbH | Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2 |
| WO2016042775A1 (en) * | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| US10626140B2 (en) | 2014-12-23 | 2020-04-21 | Forendo Pharma Ltd | Prodrugs of 17β-HSD1-inhibitors |
| IL314915B1 (en) | 2017-01-23 | 2026-02-01 | Regeneron Pharma | Variants of 17-beta-hydroxysteroid dehydrogenase and their uses |
| KR20190139869A (ko) | 2017-04-11 | 2019-12-18 | 리제너론 파마슈티칼스 인코포레이티드 | 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정 |
| FI3634975T3 (fi) | 2017-06-08 | 2024-05-03 | Organon R&D Finland Ltd | 15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa |
| US10961583B2 (en) | 2017-10-11 | 2021-03-30 | Regeneron Phramaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
| JP7507093B2 (ja) | 2018-03-21 | 2024-06-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法 |
| US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
| MX2021003077A (es) | 2018-09-19 | 2021-05-27 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresion de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y metodos de uso. |
| CN109180702B (zh) * | 2018-10-29 | 2021-11-30 | 四川大学 | 一种噻吩并嘧啶酮化合物及其用途 |
| BR112021010598A2 (pt) | 2018-12-05 | 2021-08-24 | Forendo Pharma Ltd | Compostos, método para preparação de um composto e composição farmacêutica |
| JP7612682B2 (ja) | 2019-10-15 | 2025-01-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なテトラゾール |
| PH12022550846A1 (en) * | 2019-10-15 | 2023-03-27 | Boehringer Ingelheim Pharma | Thienopyrimidones as trpa1 inhibitors |
| CA3210965A1 (en) | 2021-04-14 | 2022-10-20 | Boehringer Ingelheim International Gmbh | 3h,4h-thieno[2,3-d]pyrimidin-4-one derivatives as trpa1 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4742271B1 (es) * | 1968-06-20 | 1972-10-25 | ||
| DE2411273A1 (de) * | 1974-03-06 | 1975-09-18 | Schering Ag | Neue thieno eckige klammer auf 2,3-d eckige klammer zu pyrimidinone und verfahren zu ihrer herstellung |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| US5364847A (en) * | 1989-03-10 | 1994-11-15 | Endorecherche | Inhibitors of sex steroid biosynthesis and methods for their production and use |
| US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| JP3783810B2 (ja) | 1997-01-14 | 2006-06-07 | 第一製薬株式会社 | 新規ベンゾフラノン誘導体及びその製造方法 |
| JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| JP4166433B2 (ja) | 1997-09-11 | 2008-10-15 | 第一製薬株式会社 | ホルモン依存性疾患治療剤 |
| TR200002784T2 (tr) | 1998-03-11 | 2000-12-21 | Endorecherche, Inc | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar |
| GB9816729D0 (en) | 1998-08-01 | 1998-09-30 | Hoechst Schering Agrevo Gmbh | Substituted cyclohexylaminopyrimidines |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| AU2001296961A1 (en) | 2000-09-29 | 2002-04-08 | Bayer Pharmaceuticals Corporation | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors |
| WO2003017974A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
| AR036492A1 (es) | 2001-09-06 | 2004-09-15 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
| US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| FI20030393A7 (fi) | 2003-03-14 | 2004-09-15 | Molekyyliendokrinologian Tutkimusyksikkoe | Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi |
| GB0324792D0 (en) * | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| CN1964956B (zh) * | 2004-05-24 | 2013-03-27 | 安美基公司 | 11-β-羟基类固醇脱氢酶1型的抑制剂 |
-
2004
- 2004-06-07 US US10/861,922 patent/US7754709B2/en not_active Expired - Fee Related
- 2004-06-08 AR ARP040101982A patent/AR044649A1/es not_active Application Discontinuation
- 2004-06-08 TW TW093116412A patent/TW200504078A/zh unknown
- 2004-06-09 PL PL04739738T patent/PL1635840T3/pl unknown
- 2004-06-09 CA CA002527591A patent/CA2527591A1/en not_active Abandoned
- 2004-06-09 DK DK04739738T patent/DK1635840T3/da active
- 2004-06-09 AT AT04739738T patent/ATE401893T1/de active
- 2004-06-09 PT PT04739738T patent/PT1635840E/pt unknown
- 2004-06-09 WO PCT/EP2004/006231 patent/WO2004110459A1/en not_active Ceased
- 2004-06-09 ES ES04739738T patent/ES2311156T3/es not_active Expired - Lifetime
- 2004-06-09 JP JP2006515870A patent/JP4612628B2/ja not_active Expired - Fee Related
- 2004-06-09 BR BRPI0411319-5A patent/BRPI0411319A/pt not_active IP Right Cessation
- 2004-06-09 DE DE602004015287T patent/DE602004015287D1/de not_active Expired - Lifetime
- 2004-06-09 CN CNB2004800126362A patent/CN100502876C/zh not_active Expired - Fee Related
- 2004-06-09 EP EP04739738A patent/EP1635840B1/en not_active Expired - Lifetime
- 2004-06-09 AU AU2004246791A patent/AU2004246791B2/en not_active Ceased
- 2004-06-12 SA SA04250158A patent/SA04250158B1/ar unknown
-
2007
- 2007-12-31 US US11/967,989 patent/US20080103131A1/en not_active Abandoned
-
2010
- 2010-06-08 US US12/796,097 patent/US20100249106A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100249106A1 (en) | 2010-09-30 |
| JP2006527227A (ja) | 2006-11-30 |
| ES2311156T3 (es) | 2009-02-01 |
| HK1087331A1 (zh) | 2006-10-13 |
| BRPI0411319A (pt) | 2006-07-18 |
| AU2004246791A1 (en) | 2004-12-23 |
| SA04250158B1 (ar) | 2007-10-29 |
| ATE401893T1 (de) | 2008-08-15 |
| US20050032778A1 (en) | 2005-02-10 |
| PT1635840E (pt) | 2008-09-17 |
| EP1635840B1 (en) | 2008-07-23 |
| EP1635840A1 (en) | 2006-03-22 |
| DE602004015287D1 (en) | 2008-09-04 |
| AU2004246791B2 (en) | 2010-02-18 |
| US7754709B2 (en) | 2010-07-13 |
| CA2527591A1 (en) | 2004-12-23 |
| TW200504078A (en) | 2005-02-01 |
| CN100502876C (zh) | 2009-06-24 |
| WO2004110459A1 (en) | 2004-12-23 |
| DK1635840T3 (da) | 2008-09-01 |
| US20080103131A1 (en) | 2008-05-01 |
| CN1784234A (zh) | 2006-06-07 |
| JP4612628B2 (ja) | 2011-01-12 |
| PL1635840T3 (pl) | 2009-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044649A1 (es) | COMPUESTOS UTILES EN LA TERAPIA DE ENFERMEDADES QUE REQUIEREN LA INHIBICION DE UNA 17a - HIDROXIESTEROIDE - DEHIDROGENASA (17a- HSD) | |
| AR003449A1 (es) | Compuestos de 6-dimetilaminometil-ciclohexano sustituidos, procedimiento para su preparacion y su uso | |
| AR044650A1 (es) | Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa. | |
| ES2266459T3 (es) | Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia. | |
| ES2149215T3 (es) | Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p. | |
| AR034897A1 (es) | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos | |
| DOP2002000333A (es) | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz | |
| EA200601648A1 (ru) | Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы | |
| CO5640090A2 (es) | Inhibidores del factor inhibidor de la migracion de los macrofagos y etodo para su identificacion | |
| AR051698A1 (es) | Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa | |
| ES2051772T3 (es) | 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos. | |
| AR047529A1 (es) | Compuestos de quinolina sustituidos | |
| ECSP066456A (es) | Inhibidores macrocíclicos de la serina proteasa ns3 del virus de la hepatitis c | |
| AR034858A1 (es) | Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| AR035739A1 (es) | Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares | |
| CY1105811T1 (el) | Ενωσεις ενισχυτη ταξολης | |
| PE107798A1 (es) | Inhibidores espirociclicos de la metaloproteasa | |
| ECSP066671A (es) | Nuevos derivados de quinolina | |
| ES2148178T3 (es) | Uso de derivados de sulfamato como inhibidores de esteroide-sulfatasa. | |
| AR030591A1 (es) | Inhibidores de proteasa peptidomimetica | |
| PE20060500A1 (es) | Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes | |
| AR054475A1 (es) | Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion | |
| AR039601A1 (es) | Derivados de nitrosodifenilamina y composiciones farmaceuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologias que se caracterizan por estres oxidativo | |
| AR023510A1 (es) | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. | |
| ECSP088484A (es) | Derivados de quinazolina espirocíclicos como inhibidores de pde7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |